Ann: Next Science enters into US$5m unsecured loan facility, page-28

Do you think there is no possibility at all for a turn around?

Even if they need to capital raise at these low levels, if the studies return positive results and there is a concomitant increase in revenue or indeed a take over offer this share could really fly.

Do you see any of that as a possibility?

There is an ever increasing antibiotic resistance and an aging population with bed sores and end organ damage from diabetes causing peripheral vascular disease and healing problems. If these products add value to clinicians it is just a matter of time until adoption is more wide spread.

If the products don't stack up, then perhaps some brinkmanship to offload it or yes the writing is on the wall.

I think there is merit in these products and will probably look to add to my very small position in the future.